Opinion|Podcasts|November 27, 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Author(s)Wayne Kuang, MD, Bilal Chughtai, MD

Listen

0:00 / 0:00

Key Takeaways

OAB exhibits distinct pathophysiological differences in men and women, complicating diagnosis due to symptom overlap with BPH in men.
Engaging patients in the diagnostic process is crucial for accurate identification and management of OAB.
Delayed diagnosis and treatment of OAB can significantly impact quality of life and lead to adverse long-term clinical outcomes.
Patient advocacy and educational outreach are essential for raising awareness and improving OAB management strategies.
Primary care providers play a pivotal role in OAB management, emphasizing the importance of bladder health screening and diagnostics.

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

1:51:21 Introduction

1:52:57 Pathophysiological differences of overactive bladder (OAB) in men vs women

1:55:17 Distinguishing OAB from symptoms of benign prostatic hyperplasia (BPH)

1:56:51 Engaging the patient in the diagnostic process

2:00:55 Quality of life of OAB patients

2:04:28 Long-term clinical implications of delayed diagnosis and treatment in OAB

2:11:26 Patient advocacy for managing OAB

2:14:42 Educational outreach for OAB awareness

2:27:12 Role of primary care providers in management of OAB

2:30:22 Bladder health screening and diagnostics

2:34:47 Summary

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related to this article

October 22nd, 2026

Engy Habashy, MD, on the role of androgens in GSM management

Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.

October 22nd, 2026

How PSMA-PET shapes staging and recurrence workup in prostate cancer

Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.

October 21st, 2026

Michael Cookson, MD, reacts to Anktiva’s expanded approval in NMIBC

Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.

October 21st, 2026

Q&A: Jeffrey Spier, MD, on ARPI fatigue and the case for dose reduction

Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.

October 21st, 2026

European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC

This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.

October 20th, 2026

ESMO 2026: Key presentations across genitourinary oncology

Take a look through some of the notable data presentations at this year's ESMO Congress.

October 20th, 2026

Casdatifan shows activity across treatment settings in advanced ccRCC

The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.